


Date of Deposit: April 16, 2009



Modified Form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

<b>Application Number</b>	09/830,400
<b>Filing Date</b>	July 20, 2001
<b>First Named Inventor</b>	Nadler
<b>Group Art Unit</b>	1644
<b>Examiner Name</b>	Amy E. Juedes
<b>Attorney Docket Number</b>	20363-015 NATL

## **U.S. PATENT DOCUMENTS**

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A4	5,399,346	03/21/95	Anderson et al.	424	93.21	

## **U.S. PUBLISHED APPLICATION DOCUMENTS**

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

## **FOREIGN PATENT DOCUMENTS**

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Yes	No
	B6	WO 98/04582	LUDWIG INSTITUTE FOR CANCER RESEARCH	02/05/98		

## **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C5	Alexander et al., "Derivation of HLA-A11/K <sup>b</sup> transgenic Mice" <i>J. Immunol.</i> , 159:4753-4761 (1997)
	C6	Altman et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes", <i>Science</i> , 274:94-96 (1996)
	C7	Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", <i>Nuc. Acids Res.</i> , 25(17):3389-3402 (1997)
	C8	Anderson et al., "Intracellular Transport of Class I MHC Molecules in Antigen Processing Mutant Cell Lines", <i>J. Immunol.</i> , 151(7):3407-3419 (1993)
	C9	Anderson, W.F., "Prospects for Human Gene Therapy", <i>Science</i> , 226:401-409 (1984)
	C10	Aruga et al., "Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon $\gamma$ secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells", <i>Cancer Immunol. Immunother.</i> , 41:317-324 (1995)
	C11	Ashley et al., "Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors", <i>J. Exp. Med.</i> , 186(7):1177-1182 (1997)
	C12	Blomer et al., "Highly Efficient and Sustained Gene Transfer in Adult Neurons with a Lentivirus Vector", <i>J. Virol.</i> , 71(9):6641-6649 (1997)
	C13	Boczkowski et al., "Dendritic Cells Pulsed with RNA are Potent Antigen-presenting Cells In Vitro and In Vivo", <i>J. Exp. Med.</i> , 184:465-472 (1996)
	C14	Bohlen et al., "Differentiation of cytotoxicity using target cells labeled with europium and samarium by electroporation", <i>J. Immunol. Meth.</i> , 173:55-62 (1994)



C15	Boon et al., "Tumor antigens recognized by T lymphocytes", <i>Ann. Rev. Immunol.</i> , 12:337-365 (1994)
C16	Brigham et al., "Rapid Communication: <i>In vivo</i> Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle", <i>Am. J. Med. Sci.</i> , 298(4):278-281 (1989)
C17	Broccoli et al., "Telomerase activity in normal and malignant hematopoietic cells", <i>Proc. Nat'l. Acad. Sci. U.S.A.</i> , 92:9082-9086 (1995)
C18	Brodie et al., " <i>In vivo</i> migration and function of transferred HIV-1-specific cytotoxic T cells", <i>Nat. Med.</i> , 5(1):34-41 (1999)
C19	Brossart et al., "Identification of HLA-A2_Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies", <i>Blood</i> , 93:4309-4317 (1999)
C20	Brusic et al., "MHCPEP, a database of MHC-binding peptides: update 1997", <i>Nuc. Acids Res.</i> , 26(1):368-371 (1998)
C21	Brusic et al., "Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network", <i>Bioinformatics</i> , 14(2):121-130 (1998)
C22	Bryan et al., "Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines", <i>Nat. Med.</i> , 3(11):1271-1274 (1997)
C23	Buchovich et al., "Telomerase Regulation during Entry into the Cell Cycle in Normal Human T Cells", <i>Mol. Bio. Cell</i> , 7:1443-1454 (1996)
C24	Busch et al., "MHC Class I/Peptide Stability: Implications for Immunodominance, In Vitro Proliferation, and Diversity of Responding CTL", <i>J. Immunol.</i> , 160:4441-4448 (1998)
C25	Callan et al., "Direct Visualization of Antigen-specific CD8 <sup>+</sup> T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo", <i>J. Exp. Med.</i> , 187:1395-1402 (1998)
C26	Cayouette et al., "Adenovirus-Mediated Gene Transfer of Ciliary Neurotrophic Factor Can Prevent Photoreceptor Degeneration in the Retinal Degeneration ( <i>rd</i> ) Mouse", <i>Hum. Gene Ther.</i> , 8:423-430 (1997)
C27	Cornetta et al., "Gene Transfer into Primates and Prospects for Gene Therapy in Humans", <i>Nucl. Acid Res. Mol. Biol.</i> , 36:311-322 (1987)
C28	Cornette et al., "Periodic variation in side-chain polarities of T-cell antigenic peptides correlates with their structure and activity", <i>Proc. Nat'l. Acad. Sci. U.S.A.</i> , 92:8368-8372 (1995)
C29	Counter et al., "Stabilization of Short Telomeres and Telomerase Activity Accompany Immortalization of Epstein-Barr Virus-Transformed Human B Lymphocytes", <i>J. Virol.</i> , 68:3410-3414 (1994)
C30	Counter et al., "Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase", <i>Oncogene</i> , 16:1217-1222 (1998)
C31	De Groot et al., "Prediction of Protein Conformational Freedom From Distance Constraints", <i>Proteins: Struct. Funct. Genet.</i> , 29:240-251 (1997)
C32	DeLisi et al., "T-cell antigenic sites tend to be amphipathic structures", <i>Proc. Nat'l. Acad. Sci. U.S.A.</i> , 82:7048-7052 (1985)
C33	Dunbar et al., "Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood", <i>Curr. Biol.</i> , 8:413-416 (1998)
C34	Eglitis et al., "Retroviral vectors for introduction of genes into mammalian cells", <i>BioTechniques</i> , 6(7):608-614 (1988)
C35	Engelhard, "Structure of peptides associated with class I and class II MHC molecules", <i>Ann. Rev. Immunol.</i> , 12:181-207 (1994)



C36	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human <i>c-myc</i> Proto-Oncogene Product", <i>Mol. Cell Biol.</i> , 5(12):3610-3616 (1985)
C37	Felgner et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure", <i>Proc. Nat'l. Acad. Sci. U.S.A.</i> , 84:7413-7417(1987)
C38	Feltkamp et al., "Efficient MHC Class I-Peptide Binding is Required but does not Ensure MHC Class I-Restricted Immunogenicity", <i>Mol. Immunol.</i> , 31(18):1391-1401 (1994)
C39	Feng et al., "The RNA Component of Human Telomerase", <i>Science</i> , 269:1236-1241 (1995)
C40	Ferrari et al., "Identification of Immunodominant T Cell Epitopes of the Hepatitis B Virus Nucleocapsid Antigen", <i>J. Clin. Invest.</i> , 88:214-222 (1991)
C41	Friedman, T., "Progress Toward Human Gene Therapy", <i>Science</i> , 244:1275-1281 (1989)
C42	Gallimore et al., "A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells", <i>Eur. J. Immunol.</i> , 28:3301-3311 (1998)
C43	Gallimore et al., "Protective Immunity Does Not Correlate with the Hierarchy of Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides", <i>J. Exp. Med.</i> , 187:1647-1657 (1998)
C44	Genbank Accession No. AF018167.1, August 28, 1997, 4 pages.
C45	Gulukota et al., "Two Complementary Methods for Predicting Peptides Binding Major Histocompatibility Complex Molecules", <i>J. Mol. Biol.</i> , 267:1258-1267 (1997)
C46	Gulukota et al., "HLA allele selection for designing peptide vaccines", <i>Genetic Analysis: Biomol. Engineering</i> , 13:81-86 (1996)
C47	Hammer et al., "New methods to predict HMC-binding sequences within protein antigens", <i>Curr. Opin. Immunol.</i> , 7:263-269 (1995)
C48	Hammer et al., "Precise Prediction of Major Histocompatibility Complex Class II-Peptide Interaction Based on Peptide Side Chain Scanning", <i>J. Exp. Med.</i> , 180:2353-2358 (1994)
C49	Harle-Bachor et al., "Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes", <i>Proc. Natl. Acad. Sci. USA</i> , 93:6476-6481(1996)
C50	Herr et al., "Detection and quantification of blood-derived CD8 <sup>+</sup> T lymphocytes secreting tumor necrosis factor $\alpha$ in response to HLA-A2.1-binding melanoma and viral peptide antigens", <i>J. Immunol. Meth.</i> , 191:131-142 (1996)
C51	Herr et al., "The use of computer-assisted video image analysis for the quantification of CD8 <sup>+</sup> T lymphocytes producing tumor necrosis factor $\alpha$ spots in response to peptide antigens", <i>J. Immunol. Meth.</i> , 203:141-152 (1997)
C52	Hiyama et al., "Activation of Telomerase in Human Lymphocytes and Hematopoietic Progenitor Cells", <i>J. Immunol.</i> , 155:3711-3715 (1995)
C53	Hsu et al., "Tumor-Specific Idiotypic Vaccines in the Treatment of Patients With B-Cell Lymphoma --- Long-Term Results of a Clinical Trial", <i>Blood</i> , 89:3129-3135 (1997)
C54	Igarashi et al., "Telomerase Activity Is Induced in Human Peripheral B Lymphocytes by the Stimulation to Antigen Receptor", <i>Blood</i> , 89:1299-1307 (1997)
C55	Jager et al., "Immunoselection In Vivo: Independent Loss of MHC Class I and Melanocyte Differentiation Antigen Expression in Metastatic Melanoma", <i>Int. J. Cancer</i> , 71:142-147 (1997)
C56	Johnson, L.G., "Gene Therapy for Cystic Fibrosis", <i>Chest</i> , 107:77S-83S (1995)
C57	Kammer et al., "Molecular Mimicry of Human Cytochrome P450 by Hepatitis C Virus at the Level of Cytotoxic T Cell Recognition", <i>J. Exp. Med.</i> , 190(2):169-176 (1999)



C58	Kido et al., "Use of a retroviral vector with an internal opsin promoter to direct gene expression to retinal photoreceptor cells", <i>Curr. Eye Res.</i> , 15:833-844 (1996)
C59	Kim et al., "Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP)", <i>Nuc. Acids Res.</i> , 25(13):2595-2597 (1997)
C60	Kiyono et al., "Both Rb/p16 <sup>INK4a</sup> inactivation and telomerase activity are required to immortalize human epithelial cells", <i>Nature</i> , 396:84-88 (1998)
C61	Klingelhutz et al., "Restoration of Telomeres in Human Papillomavirus-Immortalized Human Anogenital Epithelial Cells", <i>Mol. Cell. Biol.</i> , 14(2):961-969 (1994)
C62	Klingelhutz et al., "Telomerase activation by the E6 gene product of human papillomavirus type 16", <i>Nature</i> , 380:79-82 (1996)
C63	Kolquist et al., "Expression of <i>TERT</i> in early premalignant lesions and a subset of cells in normal tissues", <i>Nat. Genet.</i> , 19:182-186 (1998)
C64	Kubo et al., "Definition of specific peptide motifs for four major HLA-A alleles", <i>J. Immunol.</i> , 152:3913-3924 (1994)
C65	Kuska, B., "Cancer Genome Anatomy Project Set for Take-off", <i>J. Nat'l. Cancer Inst.</i> , 88(24):1801-1803 (1996)
C66	Larvol et al., "In silico drug discovery: Tools for bridging the NCE gap", <i>Nat. Biotechnol.</i> , 16(Suppl.):33-34 (1998)
C67	Le Gal La Salle et al., "An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain", <i>Science</i> , 259:988-990 (1993)
C68	Lee et al., "Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients", <i>Nat. Med.</i> , 5(6):677-685 (1999)
C69	Madden, D.R., "The three-dimensional structure of peptide-MHC complexes", <i>Ann. Rev. Immunol.</i> , 13:587-622 (1995)
C70	Malakoff, D., "Biocomputing: NIH Urged to Fund Centers to Merge Computing and Biology", <i>Science</i> , 284(5421):1742 (1999)
C71	Mammi et al., Scientific Proceedings 89 <sup>th</sup> Annual Meeting of the American Association for Cancer Research, New Orleans, LA, March 28-April 1, 1998, Abstract #62
C72	Man et al., "Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice", <i>Int. Immunol.</i> , 7(4):597-605 (1995)
C73	McMichael et al., "A New Look at T Cells", <i>J. Exp. Med.</i> , 187(9):1367-1371 (1998)
C74	Meyerson et al., "hEST2, The Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization", <i>Cell</i> , 90:785-795 (1997)
C75	Miller et al., "Improved Retroviral Vectors for Gene Transfer and Expression", <i>Biotech.</i> , 7(9):980-990 (1989)
C76	Miller, A.D., "Retrovirus Packaging Cells", <i>Human Gene Ther.</i> , 1:5-14 (1990)
C77	Miyoshi et al., "Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector", <i>Proc. Nat'l. Acad. Sci. U.S.A.</i> , 94:10319-10323 (1997)
C78	Moen, R.C., "Directions in Gene Therapy", <i>Blood Cells</i> , 17:407-416 (1991)
C79	Molldrem et al., "Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells", <i>Blood</i> , 88:2450-2457 (1996)



C80	Morgenstern et al., "Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line", <i>Nucl. Acids Res.</i> , 18(12):3587-3596 (1990)
C81	Nair et al., "Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells", <i>Nature Med.</i> , 6(8):1011-1017 (2000)
C82	Nakamura et al., "Telomerase Catalytic Subunit Homologs from Fission Yeast and Human", <i>Science</i> , 277:955-959 (1997)
C83	Naldini et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector", <i>Science</i> , 272:263-267 (1996)
C84	Nijman et al., "Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes", <i>Eur. J. Immunol.</i> , 23:1215-1219 (1993)
C85	Norrback et al., "Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas", <i>Blood</i> , 88:222-229 (1996)
C86	Ono et al., "Plasmid DNAs directly injected into mouse brain with lipofectin can be incorporated and expressed by brain cells", <i>Neurosci. Lett.</i> , 117:259-263 (1990)
C87	Pamer et al., "Mechanisms of MHC Class I-restricted antigen processing", <i>Ann. Rev. Immunol.</i> , 16:323-358 (1998)
C88	Parker et al., "Peptide Binding to MHC Class I Molecules: Implications for Antigenic Peptide Prediction", <i>Immunol. Res.</i> , 14:34-57 (1995)
C89	Parker et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains", <i>J. Immunol.</i> , 152:163-175 (1994)
C90	Paul, W.E., "Antigen Processing and Presentation", in <i>Fundamental Immunol.</i> , 3 <sup>rd</sup> Edition, Chapter 17, Raven Press, Ltd., New York, NY, pages 629, 641-643 (1993)
C91	Porgador et al., "Localization, Quantitation, and In Situ Detection of Specific Peptide-MHC Class I Complexes Using a Monoclonal Antibody", <i>Immunity</i> , 6:715-726 (1997)
C92	Prowse et al., "Developmental and tissue-specific of mouse telomerase and telomere length", <i>Proc. Natl. Acad. Sci. USA</i> , 92:4818-4822 (1995)
C93	Rammensee et al., "MHC ligands and peptide motifs: first listing", <i>Immunogenetics</i> , 41:178-228 (1995)
C94	Rammensee et al., "Peptides naturally presented by MHC class I molecules", <i>Ann. Rev. Immunol.</i> , 11:213-244 (1993)
C95	Riddell et al., "T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients", <i>Nat. Med.</i> , 2(2):216-223 (1996)
C96	Rock et al., "Degradation of cell proteins and the generation of MHC class I-presented peptides", <i>Ann Rev Immunol.</i> , 17:739-779 (1999)
C97	Romero et al., "Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes", <i>J. Exp. Med.</i> , 188(9):1641-1650 (1998)
C98	Rosenberg et al., "Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction", <i>N. Engl. J. Med.</i> , 323:570-578 (1990)
C99	Rosenberg, S.A., "A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens", <i>Immunity</i> , 10:281-287 (1999)



C100	Rosenberg, S.A., "Cancer vaccines based on the identification of genes encoding cancer regression antigens", <i>Immunol. Today</i> , 18(1):175-182 (1997)
C101	Rosenberg et al., "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma", <i>Nat. Med.</i> , 4(3):321-327 (1998)
C102	Rothbard et al., "Interactions between immunogenic peptides and MHC proteins", <i>Ann. Rev. Immunol.</i> , 9:527-565 (1991)
C103	Ruppert et al., "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules", <i>Cell</i> , 74:929-937 (1993)
C104	Sahin et al., "Serological identification of human tumor antigens", <i>Curr. Opin. Immunol.</i> , 9:709-716 (1997)
C105	Salter et al., "Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid", <i>EMBO J.</i> , 5(5):943-949 (1986)
C106	Sarma et al., "Cytotoxic T Lymphocytes to An Unmutated Tumor Rejection Antigen P1A: Normal Development but Restrained Effector Function In Vivo", <i>J. Exp. Med.</i> , 189(5):811-820 (1999)
C107	Savage et al., "A Kinetic Basis For T Cell Receptor Repertoire Selection during an Immune Response", <i>Immunity</i> , 10:485-492 (1999)
C108	Scheibenbogen et al., "A Sensitive ELISPOT Assay for Detection of CD8 <sup>+</sup> T Lymphocytes Specific for HLA Class I-binding Peptide Epitopes Derived from Influenza Proteins in the Blood of Healthy Donors and Melanoma Patients", <i>Clin. Cancer Res.</i> , 3:221-226 (1997)
C109	Scheibenbogen et al., "Analysis of the TCell Response to Tumor and Viral Peptide Antigens by an IFN $\gamma$ -ELISPOT Assay", <i>Int. J. Cancer</i> , 71:932-936 (1997)
C110	Schmittel et al., "Evaluation of the interferon- $\gamma$ ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood", <i>J. Immunol. Meth.</i> , 210:167-174 (1997)
C111	Schonbach et al., "Fine Tuning of Peptide Binding to HLA-B*3501 Molecules by Nonanchor Residues", <i>J. Immunol.</i> , 154:5951-5958 (1995)
C112	Schultze et al., "Human Non-Germinal Center B Cell Interleukin (IL)-12 Production Is Primarily Regulated by t Cell Signals CD40 Ligand, Interferon $\gamma$ , and IL-10: Role of B Cells in the Maintenance of T Cell Responses", <i>J. Exp. Med.</i> , 89(1):1-11 (1999)
C113	Schumacher et al., "Direct Binding of Peptide to Empty MHC Class I Molecules on Intact Cells and In Vitro", <i>Cell</i> , 62:563-567 (1990)
C114	Sette et al., "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes", <i>J. Immunol.</i> , 153:5586-5592 (1994)
C115	Sharp, D., "Gene Therapy", <i>Lancet</i> , 337:1277-1278 (1991)
C116	Sidney et al., "Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs", <i>Immunol. Today</i> , 17(6):261-266 (1996)
C117	Stöppler et al., "The Human Papillomavirus Type 16 E6 and E7 Oncoproteins Dissociate Cellular Telomerase Activity from the Maintenance of Telomere Length", <i>J. Biol. Chem.</i> , 272(20):13332-13337 (1997)
C118	Straubinger et al., "Liposomes as Carriers for Intracellular Delivery of Nucleic Acids", <i>Meth. Enz.</i> , 101:512-527 (1983)
C119	Tolstoshev et al., "Gene expression using retroviral vectors", <i>Curr. Opin. Biotech.</i> , 1:55-61 (1990)
C120	Tompkins et al., "A europium fluoroimmunoassay for measuring binding of antigen to class II MHC glycoproteins", <i>J. Immunol. Meth.</i> , 163:209-216 (1993)



C121	Townsend et al., "Assembly of MHC Class I Molecules Analyzed In Vitro", <i>Cell</i> , 62:285-295 (1990)
C122	Valmori et al., "An Antigen-targeted Approach to Adoptive Transfer Therapy of Cancer", <i>Cancer Res.</i> , 59:2167-2173 (1999)
C123	Van den Eynde et al., "T cell defined tumor antigens", <i>Curr. Opin. Immunol.</i> , 9:684-693 (1997)
C124	Van der Burg et al., "Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability", <i>J. Immunol.</i> , 156:3308-3314 (1996)
C125	Van Pel et al., "Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes", <i>Immunol. Rev.</i> , 145:229-250 (1995)
C126	Weng et al., "Telomere lengthening and telomerase activation during human B cell differentiation", <i>Proc. Nat'l. Acad. Sci. U.S.A.</i> , 94:10827-10832 (1997)
C127	Wentworth et al., "Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome", <i>Int. Immunol.</i> , 8(5):651-659 (1996)
C128	Wolff et al., "Direct Gene Transfer into Mouse Muscle in Vivo", <i>Science</i> , 247:1465-1468 (1990)
C129	Wu et al., "Receptor-mediated Gene Delivery and Expression in Vivo" <i>J. Biol. Chem.</i> , 263(29):14621-14624 (1988)
C130	Wu et al., "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements in Vivo", <i>J. Biol. Chem.</i> , 264(29):16985-16987 (1989)
C131	Yasumoto et al., "Telomerase activity in normal human epithelial cells", <i>Oncogene</i> , 13:433-439 (1996)
C132	Yee et al., "Isolation of High Avidity Melanoma-Reactive CTL from Heterogeneous Populations Using Peptide-MHC Tetramers", <i>J. Immunol.</i> , 162:2227-2234 (1999)
C133	Letter dated April 29, 2008, enclosing Form 1037, Re: European SApplication No. 99956777.9-2402/1126872, 5 pages (2008)
C134	Priority Document for Patent Application No. 19983141, "Antigenic Peptides", Gaudernack et al., Norway, 40 pages (1999)
C135	Priority Document dated April 12, 1999, for Application No. 60/112,006, filed March 31, 1998, PCT Application No. PCT/US99/06898, 29 pages.
C136	Notice of Opposition to European Patent No. 1 126 872, in the name of Dana-Farber Cancer Institute, Inc. & Whitehead Institute for Biomedical Research, by Geron Corporation, dated September 13, 2007, 22 pages.
C137	Notice of Opposition to European Patent No. 1126872 in the name of Dana-Farber Cancer Institute, Inc. & Whitehead Institute for Biomedical Research, by Merck & Co., Inc., dated September 13, 2007, 13 pages.

\* By the waiver of 37 CFR 1.98(a)(2)(ii) a copy of the U.S. Patents A4 is not submitted.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ACTIVE 4587454v.1